Search results
Showing 7006 to 7020 of 7679 results
This guideline has been updated and replaced by NICE guideline NG212.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This quality standard has been updated and replaced by NICE quality standard 211.
This quality standard has been updated and replaced by NICE quality standard 211.
Venous thromboembolism in adults: diagnosis and management (QS29)
This quality standard has been updated and replaced by NICE quality standard QS201.
Venous thromboembolism in adults: reducing the risk in hospital (QS3)
This quality standard has been updated and replaced by NICE quality standard QS201.
This quality standard has been updated and replaced by NICE quality standard 184.
This quality standard has been updated and replaced by NICE quality standard 207.
This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.
After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.
This guidance has been updated and replaced by NICE technology appraisal guidance 887.
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
This guidance has been updated and replaced by NICE technology appraisal guidance 939.
This guidance has been updated and replaced by NICE technology appraisal guidance 477.